CannaPharmaRX (OTCMKTS:CPMD) versus Eliem Therapeutics (NASDAQ:ELYM) Critical Comparison

Eliem Therapeutics (NASDAQ:ELYM) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Valuation and Earnings

This table compares Eliem Therapeutics and CannaPharmaRX”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12 million	($0.53)	-15.98
CannaPharmaRX	N/A	N/A	$3.69 million	($0.01)	-0.88

Eliem Therapeutics is trading at a lower price-to-earnings ratio than CannaPharmaRX, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eliem Therapeutics and CannaPharmaRX’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
CannaPharmaRX	N/A	N/A	-55.33%

Insider & Institutional Ownership

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 1.3% of CannaPharmaRX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Eliem Therapeutics and CannaPharmaRX, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0	0	0	0	N/A
CannaPharmaRX	0	0	0	0	N/A

Risk and Volatility

Eliem Therapeutics has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500. Comparatively, CannaPharmaRX has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500.

Summary

CannaPharmaRX beats Eliem Therapeutics on 5 of the 8 factors compared between the two stocks.

About Eliem Therapeutics

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

About CannaPharmaRX

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.